Skip to main content
. Author manuscript; available in PMC: 2018 Apr 20.
Published in final edited form as: Clin Infect Dis. 2008 Oct 15;47(8):1105–1108. doi: 10.1086/592116

Table 2.

Direct low-density lipoprotein (LDL)-cholesterol, high-density lipoprotein (HDL)-cholesterol, and triglyceride levels at the start and end of the 6-week therapy study period.

Variable Lipid level after fasting, mean mg/dL ± SD P
Start of therapy End of therapy
Direct LDL-cholesterol level
 With ezetimibe treatment 128 ± 35.3 117 ± 30.2 .04
 With placebo 128 ± 32.3 132 ± 30.1
HDL-cholesterol level
 With ezetimibe treatment   48 ± 13.2   48 ± 11.9 NS
 With placebo   48 ± 10.9   46 ± 12.3
Triglyceride level
 With ezetimibe treatment 177 ± 90.9 173 ± 93.9 NS
 With placebo 183 ± 133.1 184 ± 101.1

NOTE. NS, not significant.